Andrew Dudum: Yes. And Jailendra, maybe just – I mean, at a high level, I think we expect the vast majority of the business in the coming years to be on being treated with a personalized offering. The underlying relationship these customers have with the platform, the stickiness, the degree of choice and customization that they’re provided the flexibility tools that they have are just meaningfully more powerful than a traditional generic treatment. So, we expect the vast majority of the business in the coming years to move towards those types of treatments.
Jailendra Singh: Okay. And then my quick follow-up, just trying to better understand your comment around pricing adjustments, flexibility in – has there been any change in your thought process given what you’ve learned about the consumer behavior competitive environment so far in the year in terms of getting more, or less aggressive with those changes in the year? And what kind of data points will you be watching or focused on, which will drive your decision to make these adjustments?
Yemi Okupe: Yes, if we can go a bit into just like what is the philosophical approach behind some of the changes that we make. And so, I think that as a management team, as a company, I think we’re less focused on what’s happening quarter-to-quarter. As Andrew mentioned, we’ve seen the consumer remain very resilient just given the types of conditions are oftentimes serving. They tend to be more resilient in nature. And so really, when we think around whether it’s pricing, or other mechanisms that we use to pass value back to consumers, what will drive the decision to do those will be primarily just around the data that we receive in experiments in identifying which categories, which areas and which types of vehicles results in the highest ROI. And so, that will be more of the governing factor versus any given concern, or opportunity in a quarter.
Jailendra Singh: Great. Thanks a lot
Operator: Your next question comes from Korinne Wolfmeyer with Piper Sandler. Please go ahead.
Korinne Wolfmeyer: Hi, good afternoon, guys. Congrats on the quarter and thanks for the question. To touch on the churn question kind of in a different way. I mean I think what we’re all selling is it hasn’t been quantified very clearly, of like what’s changed with retention and churn levels. So I guess, is there any way you can give us better color on like how many of your multi-month subscribers, are ending up doing reorders after their first initial order and how many are falling off? And then, any other detail you can give us there? Thank you.
Yemi Okupe: Yes. I think what I’d point to, Korinne, I think it’s a great question. I think there are a few data points. One is just like the previous guidance that we’ve given around long-term retention levels more of 85%. I think this whole pull-through. And if anything, I think the hope for us would be that, in fact, that gets stronger, we did see across Q1 really is just a record level of addition of net new subscribers. And that’s a function of efficiency on acquisition, but also just some of the benefits and longevity. As we continue to pass value back to consumers in the form of pricing experiments, or other value-added ads to consumers. We do expect the retention to improve in the coming quarters, but it’s very difficult to give exact quantification numbers around that.
Korinne Wolfmeyer: Got it. Thank you. Really appreciate it. And then I think you guys kind of hinted towards some new product launches. And I think, Andrew, you said, potentially GLP-1s soon. When you laid out the guidance, how much of the improvement in the guidance is coming from new product launches? And is anything getting pulled forward sooner than anticipated? And then any detail you can give us on timing of GLP-1s? And is that a, this year thing or maybe a next year thing? Any color there would be great? Thank you.
Andrew Dudum: Yes. On the GLP-1 side, definitely this year, so I would expect them soon as we talked about. But regard yes to the other side, I’d let Yemi tackle.
Yemi Okupe: Yes. And with respect to the question around guidance, Korinne, I think that really that’s less of a function of a specific categorical launch, or product launch and it relates to what it’s more of a function of as we expect continued strong demand from consumers that was similar to what we saw in the first quarter. And we do expect a continued uptick in personalized products. We’re very excited by the portfolio to come. But historically, with our guidance philosophy, we generally roll forward what we have certainty and visibility into. And so, reflected in the guidance is what we can see based upon today, and some of the impacts that we have around the products that have already launched, or imminently coming.
Korinne Wolfmeyer: Great. Thank you.
Operator: Your next question comes from George Hill with Deutsche Bank. Please go ahead.
George Hill: Good afternoon, guys, and thanks for taking the questions. I have kind of one big picture one and one small picture one, Andrew and Yemi. I guess the small picture one is, do you guys have an opinion kind of at what price point GLP-1s inflect for you from a subscription and volume perspective? And I ask that as somebody from the drug supply chain side, we see pretty significant price competition in that space and discounting in that space. So prices are coming down pretty significantly. And then my follow-up question to that is Yemi to your comments, when you talked about wanting to grow a business that has tens of millions of subscribers, kind of which disease states and product categories do you think are most important for getting to that goal? Thank you.
Andrew Dudum: Thanks George. On the GLP-1 side, I’m not sure, we probably have a perspective to share on that at this point, but I agree very interesting question and definitely dynamic, right, changing pretty near time. So I think, we’ll be able to share more on that shortly. Yes, Yemi, I’ll let you take the second half?
Yemi Okupe: Yes. And with respect to the categories, I think George, I think the benefit of our platform is that it’s both comprehensive, but at the same time, we’re very focused on the five core specialties that we operate in. Within each of these specialties, there’s tens of millions, if not hundreds of millions of subscribers for us to go after. And so, I think that we are confident in each of the specialties. They have the ability, as we mentioned in the past, to be at least $100 million or more of revenue by next year. Even that said, I think across many of these were just scratching the surface through continued innovation on the personalization side as well as continuing to broaden the product suite at different price points. We do feel very confident in our ability, to have each of these multi-hundred million dollar businesses.
George Hill: Okay. I don’t know if there’s time for a quick follow-up, but I would ask one more about GLP-1s where brand seems to be very important in that category and name brand, is very important in that category, where name brand is kind of less impolite, your name brand, Hims & Hers is important in your kind of total assets. Is that something that you view as kind of different, or like something you can cover? Or I don’t know if you can talk about how you address the marketing aspect of that category, and how it’s different from what you guys have done historically?
Andrew Dudum: Yes. I probably can’t give too much there, but I do think that when you’re talking about GLP-1 and specifically even to Dan’s question earlier around compounded GLP-1s, the safety profile and the clinical excellence around those I think it’s critical, right? And I think there’s a wide range of offerings in market with a wide range probably of clinical best practices — and I think when we bring things to market, as we’ve kind of said in the past. We don’t necessarily believe we ever need to, or should be the first to market, but we should be the best in market. And I think that’s the way we’d approach this category and its launch of being able to ensure customers that the offering, and the products are the highest quality, the highest testing and have a degree of safety and clinical excellence that is really unmatched and may know that.
George Hill: Great. Thank you.
Operator: There are no further questions at this time. This will conclude today’s conference call. Thank you all for your participation. You may now disconnect.
